SL
TEVA icon

Salomon & Ludwin’s Teva Pharmaceuticals TEVA Stock Holding History

Salomon & Ludwin’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5K Buy
853
+338
+66% +$11.3K ﹤0.01% 883
2026
Q1 		$15.5K Hold
515
– – ﹤0.01% 1265
2025
Q4 		$16K Buy
515
+42
+9% +$1.03K ﹤0.01% 1076
2025
Q3 		$9.46K Buy
473
+456
+2,682% +$8.01K ﹤0.01% 1346
2025
Q2 		$290 Sell
17
-458
-96% -$7.39K ﹤0.01% 934
2025
Q1 		$7.3K Sell
475
-284
-37% -$5.07K ﹤0.01% 490
2024
Q4 		$16.7K Hold
759
– – ﹤0.01% 381
2024
Q3 		$13.7K Buy
759
+475
+167% +$8.31K ﹤0.01% 414
2024
Q2 		$4.62K Hold
284
– – ﹤0.01% 530
2024
Q1 		$4.01K Buy
+284
New +$3.58K ﹤0.01% 657

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Salomon & Ludwin's TEVA Position: Q2 2026 in Review

Salomon & Ludwin increased its Teva Pharmaceuticals (TEVA) stake by 66% in Q2 2026, buying an estimated $11.3K and bringing the position to 853 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Salomon & Ludwin first reported a position in TEVA in Q1 2024 and has held it in 10 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Salomon & Ludwin held 853 shares of Teva Pharmaceuticals worth $28.5K as of Q2 2026.
  • Salomon & Ludwin bought 338 Teva Pharmaceuticals shares in Q2 2026, an estimated $11.3K.
  • Teva Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #883 holding.
  • Salomon & Ludwin first reported a position in Teva Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.